Sena Maria On The Benefits of Microdosing
In this episode, Sena Maria gives us an overview of her Microdosing Activation program and explains some of the benefits of microdosing.
podcast
Doug Drysdale On How CYB-003 Is Better Than Psilocybin
In this episode, James Hallifax from the Psychedelic Investor, interviews Doug Drysdale, CEO of Cybin (NYSE: CYBN). In this fantastic discussion, Doug and James discuss the potential for psilocybin (magic mushrooms) to treat depression and other mental health issues.
Interview with Sa’ad Shah, Managing Partner at Noetic Fund
In our conversation, Sa’ad gives us an overview of how his interest in philosophy led to his involvement with plant medicine, how the psychedelic industry is currently misunderstood and under appreciated, Noetic’s portfolio selection process, and more!
Interview with Awais Spall, Functional Diagnostic Nutrition Practitioner at Integrative Oasis
In this conversation, we discuss some critical points such as how he managed to heal himself through the use of Ayurveda and functional medicine which led him down the path to working with these interesting modalities, how ancestral healing has the ability to significantly influence an individual’s wellbeing overall, how his practice uses entheogens to cure physical ailments such as Traumatic Brain Injury, and more!
Interview with Zoe Helene, Founder of Cosmic Sister
In our conversation, we discuss some of Zoe’s formative experiences in the creative arts which led her down the path of plant medicine advocacy, core feminist issues and how psychedelics play a role in furthering women’s movements, why an emphasis on equity and representation within the budding psychedelic industry is crucial and still has a long way to go, and so much more.
Interview with Patrick Moher, CEO of Microdose
In this chat, he discusses some of the challenges involved in moving virtual events to an in-person conference (during a pandemic), who and what to expect at the event, and why Wonderland Miami is not just any other conference, but a one-of-a-kind experience.
Interview with Joseph Mays, IRI Program Director at Chacruna
In our conversation with Joseph, we chat a bit about some critical topics such as how psychedelics can allow us to understand the Indigenous philosophy of interrelatedness between one another and our ecosystems, the importance of considering sacred reciprocity to Indigenous peoples and their land, and how Chacruna’s Indigenous Reciprocity Initiative is making it simple for companies to give back to the societies who have cultivated psychedelic medicine.
Interview with James Lanthier, CEO of Mindset Pharma
In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.
Interview with Ian McDonald, CEO & Director of Bright Minds Biosciences
In this wide ranging interview many topics are covered, starting with the philosophy and vision of Bright Minds. We discuss most of Bright Minds’ major projects, including using new psychedelic medicines to treat chronic pain. This is exciting, since it could not only help people with chronic pain issues such as fibromyalgia, but it could also put a dent in the opioid use crisis by preventing people from being prescribed opioids by their doctors to treat pain.
Interview with Trevor Millar, Advisor, NeonMind Biosciences
In our conversation with Trevor, we have the opportunity to discuss some of the psychedelic-based treatments NeonMind is currently focused on developing to help tackle obesity. Obesity is one of the more prevalent health conditions today affecting millions of individuals worldwide. The World Health Organization has claimed that obesity has reached epidemic proportions globally with at least 2.8 million people dying each year as a result of being overweight or obese.
End of content
End of content